A Phase I/II Pharmacokinetic and Pharmacodynamic Evaluation of Oral Valganciclovir in Neonates With Symptomatic Congenital Cytomegalovirus (CMV) Infection (CASG 109).
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Pharmacodynamics; Pharmacokinetics
- 24 Jan 2008 Status changed from in progress to completed.
- 16 Oct 2005 New trial record.